{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:54:26Z","timestamp":1769583266455,"version":"3.49.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Background: Multiple Myeloma (MM) cells inhibit the development of an effective anti-\nMM immune response via defects in T cell function, ineffective antigen presentation; reduced phagocytic\ncapacity; natural killer and dendritic cell dysfunction; decreased responsiveness to IL-2 and defects\nin B cell immunity; upregulation of inhibitory pathways; and production of excessive proinflammatory\ncytokines. Moreover, immune cells including plasmacytoid dendritic cells and macrophages\ntrigger tumor cell proliferation, survival, and drug resistance. The usefulness of immunotherapies\nin MM patients has first been supported by the identification of the graft-versus-myeloma effect in\nthe context of allogeneic bone marrow (BM) transplantation. Subsequently, the inclusion of thalidomide\nand its derivatives, the Immunomodulatory Drugs (IMiDs) as well as of (immuno) proteasome\ninhibitors into MM regimens dramatically improved MM patients outcome during the last 15 years.\nDespite these unprecedented therapeutic advances MM remains an incurable disease.<\/jats:p>\n                    <jats:p>Objective: This article reviews novel immunotherapeutic approaches, which aim to restore the balance\nwithin the immunologic niche of the MM BM microenvironment.<\/jats:p>\n                    <jats:p>Method: A systematic search was conducted of the Pubmed Medline, Embase, and Cochrane Library\ndatabases for primary articles, as well as of conference abstracts (e.g., of the American Society\nof Hematology, the American Society of Clinical Oncology, the American Association of Cancer\nResearch, the European Hematology Association, and the Multiple Myeloma Workshop), practice\nguidelines, and registries of clinical trials.<\/jats:p>\n                    <jats:p>Results: The inclusion of monoclonal antibodies, immune checkpoint inhibitors, chimeric antigen\nreceptor-engineered (CAR) T cells, genetically engineered T cells, and vaccination, dendritic cellbased\ncancer vaccines in particular, into existing regimens is likely to significantly improve MM patient\noutcome in the near future.<\/jats:p>\n                    <jats:p>Conclusion: Given continuing efforts to target the immune niche within the bone marrow microenvironment\nwe are confident that the rise of immunotherapies in MM will result in long-lasting responses\nin many of our patients within the next decade.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1568009617666170214103834","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T17:08:04Z","timestamp":1487869684000},"page":"782-805","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma"],"prefix":"10.2174","volume":"17","author":[{"given":"K.","family":"Podar","sequence":"first","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, University Hospital Krems, Medical Oncology, Mitterweg 10, 3500 Krems,Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jager","sequence":"additional","affiliation":[{"name":"German Cancer Research Center (DKFZ), Applied Tumor Immunity, Heidelberg,Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009617666170214103834","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/150089\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009617666170214103834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:01:03Z","timestamp":1761332463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/150089\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009617666170214103834","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2015-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}